Roughly 80 percent of commercially-insured patients face utilization management restrictions when attempting to fill a new prescription for rheumatoid arthritis (RA) or multiple sclerosis (MS), IQVIA suggests in a new analysis.
IQVIA’s analysis includes analytics commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA).
To read more about the analysis on PhRMA’s blog, click here.
To find out how to download the report, click here.
